Late Toxicity in Breast Cancer Patients Treated With Breast-conserving Surgical Procedures and Radiotherapy Using the Simultaneous Integrated Boost Technique
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University Medical Center Groningen
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
WHO performance status 0-2.
Invasive breast cancer or ductal carcinoma in situ (DCIS).
Stage I-III breast cancer or DCIS.
Treated with curative radiotherapy of the breast (as part of breast conserving therapy) with simultaneous integrated boost technique, with or without irradiation of the regional (including internal mammary) lymph nodes.
You may not be if
Previous thoracic radiotherapy.
Previous history of malignancy, except adequately treated carcinoma in situ of the cervix or basal cell carcinoma of the skin.
Bilateral (synchrone) invasive breast cancer.
Treatment prior to surgery (i.e. neoadjuvant chemotherapy, neoadjuvant hormonal therapy, pre-operative radiotherapy).
Distant metastases at diagnosis (M1).
Unsufficient knowledge of Dutch language.
Clareo Health | Late Toxicity in Breast Cancer Patients Treated With Breast-conserving Surgical Procedures and Radiotherapy Using the Simultaneous Integrated Boost Technique
